<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016912</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-021</org_study_id>
    <nct_id>NCT01016912</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients</brief_title>
  <official_title>A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well
      tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the
      treatment of hepatitis C virus genotype 1 in chronically infected patients who are
      treatment-naïve and nonresponsive to the standard of care
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</measure>
    <time_frame>At Weeks 4 and 12 on treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>eRVR was defined as undetectable hepatitis C virus (HCV) RNA (ie, HCV RNA &lt;15 IU/mL, the lower limit of detection, target not detected) at both Weeks 4 and 12. HCV RNA levels were measured by Tobas TaqMan HCV Auto from the central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR)</measure>
    <time_frame>At Week 4 on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>RVR was defined as undetectable hepatitis C virus (HCV) RNA (ie, HCV RNA &lt;15 IU/mL, the lower limit of detection, target not detected) at Week 4. HCV RNA levels were measured by CobasTaqMan HCV Auto from the central laboratory .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</measure>
    <time_frame>At Week 12 on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>cEVR was defined as undetectable hepatitis C virus (HCV) RNA (ie, HCV RNA &lt;15 IU/mL, the lower limit of detection, target not detected) at Week 12 on treatment. HCV RNA levels were measured by Cobas TaqMan HCV Auto from the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Weeks 4, 12, and 24</measure>
    <time_frame>Follow-up Weeks 4, 12, and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR at follow-up Week 4 (SVR4), follow-up Week 12 (SVR12), and follow-up Week 24 (SVR24) is defined as undetectable hepatitis C virus (HCV) RNA (ie, HCV RNA &lt;15 IU/mL, the lower limit of detection, target not detected) at each of these timepoints. HCV RNA levels were measured by Cobas TaqMan HCV Auto from the central laboratory .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure</measure>
    <time_frame>From on-treatment Week 1 to Follow-up Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure is defined by the following 6 categories: 1.Virologic breakthrough, defined as confirmed &gt;1 log10 increase in hepatitis C virus (HCV) RNA over nadir or confirmed HCV RNA ≥limit of quantitation (LOQ) after confirmed undetectable HCV RNA while on treatment. 2. &lt;1 log10 decrease in HCV RNA from baseline at Week 4 of treatment. 3. Failure to achieve early virologic response, defined as &lt;2 log10 decrease in HCV RNA from baseline at Week 12 of treatment. 4. Detectable HCV RNA at Week 12, and HCV RNA ≥LOQ at Week 24 of treatment. 5. Detectable HCV RNA at end of treatment (including early discontinuation). 6 Relapse, defined as detectable HCV RNA during follow-up after undetectable HCV RNA levels at end of treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Death as Outcome</measure>
    <time_frame>From baseline to 30 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not has a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Grade 3 to 4 Abnormalities on Laboratory Test Results</measure>
    <time_frame>From baseline to 30 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically significant marked abnormalities in laboratory test results graded by the Division of AIDS grading table, 2004. Hemoglobin: Grade 3= &lt;7.0 to 8.9 g/dL, Grade 4= &lt;7.0 g/dL. Lymphocytes: Grade 3= 350-499 cells/mm^3, Grade 4= &lt;350 cells/mm^3. Neutrophils: Grade 3= 500-999 cells/mm^3, Grade 4= &lt;500 cells/mm^3. White blood cells (WBC): Grade 3= 1000-1499 cells/mm^3, Grade 4= &lt;1000 cells/mm^3. Alanine aminotransferase (ALT): Grade 3= 5.1-10*upper limit of normal (ULN), Grade 4= &gt;10.0*ULN. Aspartate aminotransferase (AST): Grade 3= 5.1-10*ULN, Grade 4= &gt;10.0*ULN. Total bilirubin: Grade 3= 2.6-5*ULN, Grade 4= &gt;5.0*ULN.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Responder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Responder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052</intervention_name>
    <description>Tablets, Oral, 10 mg, daily, 24-48 weeks</description>
    <arm_group_label>Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052</intervention_name>
    <description>Tablets, Oral, 60 mg, daily, 24-48 weeks</description>
    <arm_group_label>Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, daily, 48 weeks</description>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks</description>
    <arm_group_label>Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <other_name>PegIntron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks</description>
    <arm_group_label>Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <arm_group_label>Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)</arm_group_label>
    <other_name>Rebetol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients chronically infected with hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load ≥10*5* IU/mL at screening

          -  Naïve or nonresponsive to the current standard of care

        Key Exclusion Criteria:

          -  Cirrhosis

          -  Hepatocellular carcinoma

          -  Coinfection with hepatitis B virus, HIV-1 or HIV-2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hiroshima City</city>
        <state>Hiroshima</state>
        <zip>734-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawasaki-Shi</city>
        <state>Kanagawa</state>
        <zip>2138587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suita-Shi</city>
        <state>Osaka</state>
        <zip>5650871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Iruma-Gun</city>
        <state>Saitama</state>
        <zip>3500495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>105-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>November 19, 2009</firstreceived_date>
  <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
